NBIX
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN MASTER SCORE – NBIX (Neurocrine Biosciences)
| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 74 | Hyper-growth biotech (EPS growth +120.3% YoY) with strong forward momentum, attractive forward PE (20.94), but elevated earnings multiple and moderate institutional visibility due to earnings data gaps. | 6–12M |
| SA Quality/Value Composite | B | 72 | Trailing PE 35.06 is elevated but justified by 120.3% EPS growth YoY and PEG ratio 0.29 (highly accretive). Forward PE 20.94 signals compression. No dividend. Hyper-growth flag active. | 6–12M |
| Zacks Earnings Momentum | A- | 78 | EPS growth +120.3% YoY exceptional. Revenue growth +28.6% YoY solid. Earnings surprise and revision data not disclosed; forward PE compression suggests analyst confidence in sustained delivery. | 3–6M |
| Institutional & Smart Money Flow | C+ | 62 | 52-week return +35.6% indicates sustained institutional demand. Recent -10.1% daily decline from $185.50→$166.80 creates tactical entry for conviction holders. Volume data unavailable; crowding assessment limited. | 1–3M |
| Growth Sustainability & Moat | B+ | 76 | Biotechnology sector implies IP-backed pipeline. +120% EPS growth YoY and +28.6% revenue growth YoY suggest durable clinical/commercial execution. Beta 0.38 (low) indicates defensive posture. Earnings date and detailed pipeline visibility constrained. | 6–12M |
| Valuation & Safety (Pre-Penalty) | B | 71 | PEG 0.29 highly attractive for growth rate. Forward PE 20.94 fair for biotech growth profile. 52-week range $122.14–$186.12 shows healthy volatility; current $166.80 within mid-to-upper range. No debt stress signals visible. | 6–12M |
| Penalty Overlay | -8 | −8 | Data gaps: earnings date, target price, dividend policy, revenue TTM, balance sheet detail. Biotech sector inherent execution risk (clinical/regulatory). No profitability flag raised, but earnings date opacity limits near-term catalyst precision. | 1–3M |
| CONFIDENCE SCORE | B | 70 | Strong quantitative metrics (growth, PEG, valuation multiple). Limited visibility on earnings schedule, analyst target consensus, and near-term catalyst timing. Sector-level biotech volatility accepted. | 3–6M |
| Volatility & Drawdown Risk | C | 61 | Beta 0.38 (low) supports defensive profile. Recent −10.1% intraday decline demonstrates sector/stock-specific sensitivity. 52-week drawdown from $186.12→$164.56 (−11.6%) moderate. Biotech earnings volatility typical. | 1–3M |
| Crowding Risk Flag | CAUTION | 65 | 52-week return +35.6% and hyper-growth flag suggest institutional attention. Volume data unavailable. Recent sharp decline may indicate profit-taking or sector rotation. Position sizing recommended for concentrated biotech exposure. | 1–3M |
Key Snapshot
Current Price
$166.80
Change (Session)
−$18.70 (−10.1%)
Trailing PE
35.06
Forward PE
20.94
PEG Ratio
0.29
EPS Growth YoY
+120.3%
Revenue Growth YoY
+28.6%
Beta
0.38
52-Week Return
+35.6%
Market Cap
$16.78B
Peer & Sector Context
NBIX operates in the Biotechnology sector, characterized by high growth volatility and clinical/regulatory execution risk. Within mid-cap biotech ($10B–$20B), NBIX's combination of 120%+ EPS growth, 29% PEG multiple, and low beta (0.38) positions it as a rare profitability-inflected growth story. Comparable biotech peers typically trade trailing PE 25–45; NBIX's 35.06 is mid-range but justified by aggressive earnings acceleration. The forward PE compression to 20.94 implies analyst consensus for earnings sustainability, suggesting market confidence in pipeline advancement or commercial ramp.
Two-Horizon Outlook
| Horizon | Thesis | Key Catalysts & Risks |
|---|---|---|
| 1–3 Months (Near-Term) | Tactical volatility opportunity. Recent −10.1% decline may signal profit-taking or sector-wide biotech weakness. Low beta (0.38) and hyper-growth fundamentals suggest mean reversion toward $175–$180 if momentum recouples. Limited visibility on earnings date creates short-term uncertainty. |
Catalysts: Earnings release (date not disclosed), clinical trial updates, commercial execution metrics. Risks: Sector rotation, competitive pipeline announcements, margin pressure if revenue mix shifts. |
| 6–12 Months (Medium-Term) | Strong structural upside. 120% EPS growth YoY and 28.6% revenue growth are durable if pipeline advances as expected. Forward PE 20.94 offers room for multiple expansion if near-term earnings beats sustain. Biotech moat (IP, regulatory barriers) typically endures 3–5 year horizon. |
Catalysts: Next 2–3 quarter earnings, pipeline progression (Phase 3 readouts, FDA approvals), analyst upgrades. Risks: Clinical trial failures, competitive generic/biosimilar pressure, margin compression, loss of exclusivity on key programs. |
ESEN VERDICT (B+ | 74): NBIX is a high-conviction growth biotech with exceptional earnings momentum (EPS +120% YoY), attractive valuation (PEG 0.29, forward PE 20.94), and low systematic risk (beta 0.38). Recent −10.1% decline creates tactical entry for patient capital; however, missing earnings date and analyst consensus data warrant position discipline. Suitable for growth-oriented, biotech-comfortable portfolios with 6–12 month horizon. Near-term volatility expected; avoid size on sharp rallies.
AI STOCK INSIGHT
NBIX Stock Analysis & Forecast
Is NBIX a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
NBIX Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, NBIX shows balanced risk-reward characteristics.
Should You Buy NBIX Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in NBIX.